What is Radformation?
Radformation is dedicated to expediting cancer patient treatment through the development of safer and more intelligent radiation treatment plans. The company's core objective is to empower clinicians by automating and standardizing the treatment planning workflow, thereby making high-quality cancer care more accessible globally. By addressing the increasing cancer rates and the disparities in care access, Radformation aims to reduce the global impact of cancer and improve patient outcomes. Their unwavering commitment lies in delivering reliable, high-quality solutions that foster standardized care for all individuals in need.
How much funding has Radformation raised?
Radformation has raised a total of $2.6M across 3 funding rounds:
Private Equity
$663K
Angel/Seed
$1.6M
Debt
$350K
Private Equity (2017): $663K, investors not publicly disclosed
Angel/Seed (2018): $1.6M led by Brooklyn Bridge Ventures
Debt (2020): $350K supported by PPP
Key Investors in Radformation
Brooklyn Bridge Ventures
Brooklyn Bridge Ventures is a venture capital firm that typically invests in early-stage companies. Their involvement suggests a belief in Radformation's foundational technology and growth potential.
PPP
Public-Private Partnership
What's next for Radformation?
With the recent influx of enterprise-level capital, Radformation is poised to further its mission of revolutionizing radiation oncology. The company's focus on automation and standardization in treatment planning suggests a strategic direction towards scaling its operations and expanding its technological reach. Future endeavors will likely involve enhancing its platform's capabilities, forging new partnerships within the healthcare ecosystem, and potentially exploring new markets to bring its advanced solutions to a wider patient population. This latest financing round is a testament to the company's potential to significantly impact cancer care delivery worldwide.
See full Radformation company page
